GLP-1semaglutidelymphedemaglp-1 receptor agonists

Review says GLP-1 lymphedema evidence supports study, not clinical adoption

Authors cite case reports, one retrospective cohort and bench work showing semaglutide increases pumping in isolated collecting lymphatic vessels.

By Maren Holt · Senior Reporter, GLP-1

Oct 7 20:00 ETSource: Frontiers in endocrinology

The wire

01The Frontiers in Endocrinology review separates two possible mechanisms: weight loss unloading a compromised lymphatic system, and direct GLP-1 receptor signalling in lymphatic endothelial cells.
02Clinicians seeing patients with lymphedema on GLP-1 therapy have reports of reduced limb volume and lower breast cancer-related lymphedema incidence, but no controlled efficacy data.
03The authors say GLP-1 receptor agonists should still be prescribed for established metabolic indications, and call for weight-matched comparison groups and functional imaging in prospective trials.

From the source

GLP-1 receptor agonists and lymphedema: from weight loss to potential direct modulation of lymphatic function
Frontiers in endocrinology · 2026 · Merzel Šabović EK, Janić M, Planinšek Ručigaj T et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42922894/